Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

News & Events

Blog

Use the search feature below to stay up to date on our latest blog posts.

FDA Endorses Human-Relevant Nonclinical Models: A Welcome Shift for Monoclonal Antibody Development

04.17.25

Ruling the Future: How the ACLA’s LDT Court Victory and Europe’s IVDR Are Shaping Bioanalytical Laboratories

04.03.25

Reframing the Definition of Obesity

02.24.25

GLP-1 Agonist-Induced Delayed Gastric Emptying – A Clinical Pharmacology Perspective

11.05.24

How Healthy Volunteer Studies can Accelerate Oncology Drug Development

09.11.24

Key Clinical Pharmacology Studies to Support Biologic Drug Regulatory Submission

05.22.24

12 Questions to Help Guide Renal Impairment PK Study Design

03.26.24

Adaptive Trial Designs

06.29.22

A Decade of Innovative Technology to Accelerate Drug Development

08.04.20

The Platforms and Promise of COVID-19 Vaccines

07.07.20

Celebrating a Decade of Biosimilars Development

06.30.20

Open for Business: Early Phase Clinical Drug Development during the COVID-19 Pandemic

06.18.20

COVID-19, Kawasaki and the Cytokine Storm

06.02.20

Capturing the Cytokine Storm: Using Biomarkers in COVID-19 Trials

04.27.20

Pharmabiotics – Spreading Culture to Therapeutic Drugs

04.01.20

COVID-19 Vaccines in Development

03.19.20

Backing the Biosimilar Boon

07.02.19

Innovations in COPD – A Breath of Fresh Air

01.25.19

Entering the NASH Race: Tips for Early Clinical Development

10.15.18

The Next Frontier of Pharmacology: Micro Drug Delivery

07.09.18

Know Your Numbers Campaign

04.08.18

Prediabetes, the New Normal in Early Clinical Research

11.06.17

Supporting the Next Major Health Epidemic

08.19.16

Load More